Notice2023-24995
Foreign-Trade Zone (FTZ) 61, Notification of Proposed Production Activity; AIAC International Pharma, LLC; (Pharmaceutical Products); Arecibo, Puerto Rico
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
November 14, 2023
Issuing agencies
Commerce DepartmentForeign-Trade Zones Board
Full Text
<html>
<head>
<title>Federal Register, Volume 88 Issue 218 (Tuesday, November 14, 2023)</title>
</head>
<body><pre>
[Federal Register Volume 88, Number 218 (Tuesday, November 14, 2023)]
[Notices]
[Page 77952]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2023-24995]
[[Page 77952]]
-----------------------------------------------------------------------
DEPARTMENT OF COMMERCE
Foreign-Trade Zones Board
[B-57-2023]
Foreign-Trade Zone (FTZ) 61, Notification of Proposed Production
Activity; AIAC International Pharma, LLC; (Pharmaceutical Products);
Arecibo, Puerto Rico
AIAC International Pharma, LLC submitted a notification of proposed
production activity to the FTZ Board (the Board) for its facility in
Arecibo, Puerto Rico within Subzone 61D. The notification conforming to
the requirements of the Board's regulations (15 CFR 400.22) was
received on November 7, 2023.
Pursuant to 15 CFR 400.14(b), FTZ production activity would be
limited to the specific foreign-status material(s)/component(s) and
specific finished product(s) described in the submitted notification
(summarized below) and subsequently authorized by the Board. The
benefits that may stem from conducting production activity under FTZ
procedures are explained in the background section of the Board's
website--accessible via <a href="http://www.trade.gov/ftz">www.trade.gov/ftz</a>. The proposed finished
product(s) and material(s)/component(s) would be added to the
production authority that the Board previously approved for the
operation, as reflected on the Board's website.
The proposed finished product is Janumet[supreg] XR tablets
(sitagliptin and metformin hydrochloride extended release) (duty-free).
The proposed foreign-status material/component is metformin
hydrochloride active pharmaceutical ingredient (duty-free).
Public comment is invited from interested parties. Submissions
shall be addressed to the Board's Executive Secretary and sent to:
<a href="/cdn-cgi/l/email-protection#d9bfada399adabb8bdbcf7beb6af"><span class="__cf_email__" data-cfemail="781e0c02380c0a191c1d561f170e">[email protected]</span></a>. The closing period for their receipt is December 26,
2023.
A copy of the notification will be available for public inspection
in the ``Online FTZ Information System'' section of the Board's
website.
For further information, contact Christopher Wedderburn at
<a href="/cdn-cgi/l/email-protection#3c7f544e554f126b595858594e5e494e527c484e5d5859125b534a"><span class="__cf_email__" data-cfemail="ecaf849e859fc2bb898888899e8e999e82ac989e8d8889c28b839a">[email protected]</span></a>.
Dated: November 7, 2023.
Elizabeth Whiteman,
Executive Secretary.
[FR Doc. 2023-24995 Filed 11-13-23; 8:45 am]
BILLING CODE 3510-DS-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on November 14, 2023.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.